VCBeat Health Contact Us
Home A New Era in Obesity Treatment: EU Approves Novo Nordisk's GLP-1 Agonist Wegovy (Semaglutide 2.4 mg) – 18% Weight Loss Over 68 Weeks!

A New Era in Obesity Treatment: EU Approves Novo Nordisk's GLP-1 Agonist Wegovy (Semaglutide 2.4 mg) – 18% Weight Loss Over 68 Weeks!

Jan 15, 2022 02:03 CST Updated 02:03
Novo Nordisk

Insulin Developer and Manufacturer

European Commission

The European Commission, abbreviated as the EU Commission, is a supranational body under the European Union. Within the EU political system, the European Commission primarily undertakes executive tasks, thus being roughly equivalent to the government in a national system. However, the European Commission has other functions as well. In particular, except for the few circumstances specified in the treaties, the European Commission is the only institution with legislative power in the EU legislative process.


News on January 14, 2022 /BioValleyBIOON/ -- According to the information from the EU New Drug Approval Database, Novo NordiskWegovy (semaglutide) 2.4mg Subcutaneous InjectionAlready approved in the EU:This medication is a once-daily glucagon-like peptide-1 (GLP-1) analog used for long-term weight management in obese adult patients.. Previously, Wegovy had been approved in the United States in June 2021.FDAApproval, obtained in September 2021 from the UK Medicines andHealth ProductsApproved by the Administration (MHRA) for long-term weight management. In terms of US regulation, Novo Nordisk submitted a Priority Review Voucher (PRV) to expedite the review.

Wegovy is specifically applicable to: as an adjunct to a low-calorie diet and increased exercise, for the treatment of obesity (BMI≥30kg/m²), or overweight (BMI≥27kg/m²) with at least one weight-related comorbidity (such as abnormal blood sugar,Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) in adult patients.

It is worth mentioning that,Wegovy is the first and only once-weekly GLP-1 receptor agonist approved for weight management in patients with obesity.The aforementioned regulatory approvals of Wegovy are all based on the results of the STEP 3a phase clinical trial program, which involved more than 4,500 obese or overweight adult patients. In the absence of type 2DiabetesConducted among the subjectsClinical TrialIn China,Obesity Patients Treated with Wegovy Achieved an Average Weight Loss of 17-18% Over 68 Weeks. Throughout the project,Wegovy is safe and well-tolerated, with the most commonAdverse ReactionsGastrointestinal reaction。

Despite the best effortsWeight Loss, but due to physiological responses that favor weight regain, many individuals with obesity still struggle to achieve and maintain weight loss.As aWeight LossUnprecedented efficacyWeight LossThe approval and market launch of Wegovy marks a new era in the treatment of obesity.

Obesity is a chronic disease that requires long-term treatment and is associated with many serious health consequences and reduced life expectancy. Obesity-related complications include type 2 diabetes.Diabetes, heart disease, obstructive sleep apnea, chronic kidney disease, non-alcoholic fatty liver, and cancer.

Semaglutide (司美格鲁肽) is a human glucagon-like peptide-1 (GLP-1) analog., promoting insulin secretion and inhibiting glucagon secretion through a glucose concentration-dependent mechanism, which can benefit type 2DiabetesThe patient's blood glucose levels have significantly improved, and the risk of hypoglycemia is low. In addition, semaglutide can also induce weight loss by reducing appetite and decreasing food intake.Weight Loss. In addition, semaglutide can significantly reduce type 2DiabetesRisk of Major Adverse Cardiovascular Events (MACE) in Patients.

In China,NovoTai® (English trade name: Ozempic, semaglutide, injectable semaglutide, formerly known as somaglutide) was approved by the National Medical Products Administration (NMPA) in April 2021 for the treatment of patients with type 2 diabetes (T2D) to improve glycemic control.NovoTai® is a new long-acting glucagon-like peptide-1 (GLP-1) analog with a half-life of up to 7 days, suitable for once-weekly injection with stable blood drug concentration.

In China, the number of people with diabetes exceeds 129.8 million, of which only 15.8% have achieved blood glucose control targets. Diabetes can easily lead to macrovascular disease, microvascular disease, and other complications, seriously affecting the quality of life of patients and increasing the burden of illness. Among these, cardiovascular disease is the leading cause of death for patients with type 2 diabetes. In China, one in three diabetes patients also suffers from cardiovascular disease. Poor blood glucose control, along with inadequate management of cardiovascular metabolic indicators such as blood pressure, blood lipids, and weight, are the main reasons for the high incidence of complications among Chinese diabetes patients. Therefore, diabetes treatment needs to focus on comprehensive patient benefits, balancing blood glucose control with cardiovascular outcomes, and managing multiple risk factors comprehensively.

As a once-weekly GLP-1 blockbuster product, NovoTai® employs breakthrough technology to extend its half-life to 7 days, achieving once-weekly dosing, potent blood sugar control, precise target achievement, and comprehensive cardiovascular metabolic benefits. It provides Chinese patients with type 2 diabetes a more effective, convenient, and safer treatment option. The approval of NovoTai® will further drive the transformation of diabetes treatment methods and concepts in China, support comprehensive disease management, improve long-term treatment outcomes, and help patients return to a peaceful life. (Bioon.com)